Provided by Tiger Trade Technology Pte. Ltd.

Nexalin Technology, Inc.

0.3190
+0.00361.14%
Volume:105.69K
Turnover:32.82K
Market Cap:7.02M
PE:-0.69
High:0.3199
Open:0.3132
Low:0.3021
Close:0.3154
52wk High:2.00
52wk Low:0.3021
Shares:22.01M
Float Shares:19.29M
Volume Ratio:0.90
T/O Rate:0.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4623
EPS(LYR):-0.5016
ROE:-240.25%
ROA:-119.22%
PB:4.62
PE(LYR):-0.64

Loading ...

Nexalin Technology Wins US Patent Protecting Neurostimulation Method Through 2042

MT Newswires Live
·
Jun 04

Nexalin wins US patent for dynamic frequency brain stimulation targeting anxiety, depression, insomnia

Reuters
·
Jun 04

Maxim Group Reaffirms Their Buy Rating on Nexalin Technology, Inc. (NXL)

TIPRANKS
·
May 21

Nexalin closes acquisition of PONM digital health platform for USD 1.3 million

Reuters
·
May 19

Nexalin Acquires AI-Integrated Digital Health Platform Behind Halo™ Clarity and Nexalin Neurocare™ Ahead of Planned FDA Pivotal Trial

THOMSON REUTERS
·
May 19

Nexalin Q1 FY26 net loss widens 5% to $2.1 million; revenue drops 64% to $14,950

Reuters
·
May 09

Nexalin Technology Inc expected to post a loss of 10 cents a share - Earnings Preview

Reuters
·
May 08

Nexalin study shows insomnia improvement with 15 mA, 77.5 Hz brain stimulation

Reuters
·
Apr 28

Morgan Stanley Sticks to Their Buy Rating for Nuix Ltd. (NXL)

TIPRANKS
·
Apr 27

Nuix Ltd. (NXL) Gets a Buy from RBC Capital

TIPRANKS
·
Apr 24

BRIEF-Nexalin Technology Advances Clinical Trial Of HALO Clarity Toward Q2 2026 Enrollment

Reuters
·
Apr 22

Nexalin Technology enters agreements to advance HALO Clarity trial

TIPRANKS
·
Apr 22

Nexalin Technology Advances Pivotal Clinical Trial of Halo™ Clarity Toward Q2 2026 Enrollment

THOMSON REUTERS
·
Apr 22

Nexalin Technology: Patient Enrollment Currently Expected to Begin in Q2 of 2026

THOMSON REUTERS
·
Apr 22

Nexalin targets Q2 2026 enrollment for pivotal HALO Clarity insomnia trial

Reuters
·
Apr 22

BUZZ-U.S. STOCKS ON THE MOVE-Nike, PNC Financia, OSI Systems

Reuters
·
Apr 16

Nexalin targets Q2 FDA Q-Submission update for Alzheimer’s De Novo pathway

Reuters
·
Apr 15

Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China

THOMSON REUTERS
·
Apr 15

Nexalin Technology Inc: Plans to Submit an Amended FDA Q-Submission Application Based on Strategy Meetings in Q2 2026

THOMSON REUTERS
·
Apr 15

Nexalin to present at RedChip-hosted live investor webinar with Q&A session

Reuters
·
Apr 14